Reported Earnings • Apr 06
Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024) Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024). New Risk • Mar 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 126% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (126% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap). New Risk • Feb 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$7.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). New Risk • Dec 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$18.9m market cap). Reported Earnings • Oct 05
First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024) First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. New Risk • Sep 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$24.0m market cap). New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$33.6m market cap). Reported Earnings • Apr 27
Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023) Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings. Annuncio • Nov 07
Zhongchao Inc., Annual General Meeting, Dec 18, 2024 Zhongchao Inc., Annual General Meeting, Dec 18, 2024, at 09:00 China Standard Time. Location: nanxi creative center, suite 218, 841 yanan middle road, jingan district, shanghai, China New Risk • Oct 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 116% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap). Annuncio • Oct 02
Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million. Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,094,000
Price\Range: $0.3
Discount Per Security: $0
Transaction Features: Registered Direct Offering New Risk • Oct 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Market cap is less than US$10m (US$3.39m market cap). Reported Earnings • May 02
Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022) Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Reported Earnings • Dec 27
First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022) First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$20.8m market cap). New Risk • Nov 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$22.4m market cap). Annuncio • Sep 26
Zhongchao Inc. Introduces Pro-Based Disease Management Model for Lung Cancer Patients Zhongchao Inc. announced the introduction of its Patient-Reported Outcome (PRO)-based symptom management model. This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality. Many lung cancer patients are grappling with a multitude of symptoms throughout their treatment process, including but not limited to fatigue, reduced appetite, nausea, and approximately 34 other symptoms. These symptoms can lead to emotional turmoil towards patients, manifesting as anxiety or depression, severely impacting patients' life quality and their overall recovery process. The PRO-based symptom management method prioritizes genuine feedbacks from patients about their health conditions, which aids in accurately identifying underlying health concerns and enhancing overall well-being. A study published in the "Journal of Clinical Oncology" in 2022 also highlighted that a PRO-driven model integrating proactive Symptom Monitoring, Alerting, and Response System can significantly reduce post-discharge symptoms and complications in lung cancer patients, accelerate their post-operative recovery and receive high satisfaction from patients. Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients. The expert-led seminars could guide patients and offer direct engagement through mobile applications to answer their queries virtually. The seminars ensure patients fully understand their treatment journey and can enhance their adherence to treatment protocols. Zhongchao also provides a suite of resources through mobile applications, including, among the others, educational contents, disease follow-up visits, lifestyle advice, drug aids information and other support services. To facilitate efficient and one-on-one patient communications, Zhongchao has established robust follow-up channels through various platforms such as phones, WeChat, and text messages, staffed by dedicated disease management specialists. Unlike the existing patient management services, which focus primarily on medical aspects such as Duration of Therapy, the newly introduced PRO-based management model shifts the focus towards patients' own experiences and feelings about their health, bringing a fresh perspective into patient care. By actively collecting and analyzing patient feedback on physical symptoms, emotional states, self-perceptions and other PRO data, the Company is able to continually refine its management methods, aiming to enhance the living standards and well-being of lung cancer patients. Reported Earnings • May 14
Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021) Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Annuncio • Feb 09
Zhongchao Inc. Announces the Application of ChatGPT to Elevate Patient Management Service Capabilities and Experience Zhongchao Inc. announced the application of ChatGPT (Chat Generative Pre-trained Transformer) for content creation and patient interactions to enhance the capabilities in delivering quality experience of patient management services. ChatGPT is a language model developed by OpenAI that learns and produces conversational content through natural language processing powered by artificial intelligence technology to interact with users in chat and continuously learn to improve the user experience. The Sunshine Health Forums and Zhongxin, both operated by the PRC operating entities that Zhongchao consolidates the financial statements with through certain contractual agreements, provide medical knowledge education and treatment process management services with patients through a comprehensive array of resources, including media matrix, anti-cancer encyclopedia, online consultation, and medication management. These platforms offer patients with instant answers and clarifications for complex and professional issues and questions encountered during self-diagnosis, diagnostic and treatment process, serving as a valuable reference for patients' consultation, treatment, and health maintenance. Given the wide variety of human diseases and the huge amount of medical information, patient management requires efficient production of massive medical content and prompt patient interactions. In a further effort to enhance patient experience, Zhongchao will apply ChatGPT on the existing platforms of Wechat Public Account and Mini-Program on WeChat to improve the efficiency of producing graphics, videos, and other contents, promptly respond and interact with patients, and manage patient emotions and experiences. Zhongchao places a strong emphasis on delivering a superior patient experience. In addition, patients will be alerted that contents provided by ChatGPT will be solely for reference and convenience to users and shall not be relied on for diagnostic or treatment purposes. To address patients' demand for personalized services, the Company may plan to harness ChatGPT's power of advanced thinking and computing capabilities to develop customized disease management models and intelligent tools that cater to the specific needs and conditions of each patient, ensuring patients receiving individualized and tailored services regardless of their varying disease types, stages, health conditions, and mental states. Reported Earnings • Dec 18
First half 2022 earnings released: EPS: US$0.004 (vs US$0.04 in 1H 2021) First half 2022 results: EPS: US$0.004 (down from US$0.04 in 1H 2021). Revenue: US$7.30m (down 15% from 1H 2021). Net income: US$93.5k (down 91% from 1H 2021). Profit margin: 1.3% (down from 12% in 1H 2021). The decrease in margin was driven by lower revenue. Annuncio • Dec 06
Zhongchao Inc. Establishes SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform Zhongchao Inc. announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer. The SID Platform created by Zhongchao targets physicians from different levels and covers comprehensive disciplines of liver cancer treatment: hepatobiliary surgery, interventional and medical oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer disciplines, the SID Platform designs and provides clinical diagnosis and treatment education courses in liver cancer and provides a technical platform for clinicians to share experiences and discuss clinical challenges. As of now, the courses on the SID Platform were taken approximately 290,000 times by liver cancer physicians. Zhongchao believes that its SID Platform provides a platform for liver cancer physicians, especially for junior and intermediate physicians to present themselves, learn knowledge and techniques, and communicate with peers, which promotes new liver cancer treatment concepts such as conversion therapy, comprehensive patient management and standardized interventional treatments. Zhongchao expects its SID Platform to serve as a new model of promotion and education platform, contribute to the lifelong learning and professional development of liver cancer physicians, and eventually benefit liver cancer patients. Board Change • Dec 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Kevin Dean Vassily was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • Sep 02
Zhongchao Inc. Announces Its New Strategy Extension Focusing on the Oncology and Other Major Disease Management Zhongchao Inc. announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services. The Company has implemented several strategic initiatives to transform to the new "Medical-Pharmaceutical-Patient" model. In 2021, Zhongchao launched patient management business focusing on the professional field of tumor and rare disease through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin"), which was the important first step of the transform. The strategy to extend business model was driven by the increased demands of "patient-oriented" healthcare in China. Management have been closely observing and monitoring such service model that is to provide medical services and disease management tailored to individual patient and allow patient to actively initiate and participate in health management and disease treatment since its appearance in 2021. It is worth to mention that the Company's self-developed patient management system successfully improved Duration of Therapy ("DOT") by 40.4% for liver cancer patients, contributing to the maximum efficiency of drugs, successful treatment and longer patient survival terms, as compared to patients without using the management system, based on the data collected by the Company during a period from November 2017 to September 2021. As a result, the Company plans to continue the development of patient management services through Zhongxin. As of now, Zhongxin provides comprehensive disease education and management services for tumor patients receiving treatment. Through services such as drug aids, disease follow-up visits, medication management, and cancer education promotion, Zhongxin helps tumor patients reduce the economic burden of treatment and promote the completion the treatment process, resulting in the best treatment effect and improvement the quality of life for the patients. As of now, more than hundreds of thousand oncology Patients have used either the application developed by Zhongxin or WeChat network service platform to connect patients with Zhongxin's hotline center and service commissioner system and received disease management support. Annuncio • Jun 15
Zhongchao Inc., Annual General Meeting, Jul 28, 2022 Zhongchao Inc., Annual General Meeting, Jul 28, 2022, at 21:00 China Standard Time. Location: Nanxi Creative Center, Suite 218, 841 Yan’an Middle Road Jing’An District, Shanghai, People’s Republic of China Jing'an China Agenda: To elect each of the five directors named in this notice to shareholders (the “Proxy Statement”) to hold office until the next annual meeting of shareholders and until his/her respective successor is elected and duly qualified; and To approve the appointment of Marcum Bernstein & Pinchuk LLP, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022. Annuncio • May 03
Zhongchao Inc. announced delayed 20-F filing On 05/02/2022, Zhongchao Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment deteriorated over the past week After last week's 39% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 19x in the Consumer Services industry in the US. Total loss to shareholders of 44% over the past year. Annuncio • Aug 26
Zhongchao Inc.'s Subsidiary Shanghai Zhongxin Medical Technology Co., Ltd Expands Patient Management Business to Ovarian Cancer Market Zhongchao Inc. announced its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin") provides patient follow-up management services for ovarian cancer patients from Zeyoulexiang Patient Assistance Project (the "Project"), helping ovarian cancer patients improve treatment outcomes and eventually increase survival rate. The Project, managed by Bethune Charitable Foundation, provides assistance to female patients in mainland China who meet the standards to take Niraparib, an anti-cancer medication. Through the all-in-one patient management system ("All-in-One System") developed by the Company, patients can record, track and view various indications of their bodies and disease during the medication and receive early warnings of potential disease progression to manage adverse reactions and psychological problems during medication and improve their adherence to treatment and treatment safety. In addition, the digital follow-up function embedded in the All-in-One System allows patient management specialists and physicians to provide one-on-one medication guidance and lifestyle advice for patients to ensure correct drugs usage and response to adverse reactions, improving the treatment experience. Annuncio • May 29
Zhongchao Inc. Launches New Line of Business Zhongchao Inc. announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. Zhongchao has been closely following up on the new study and research of tumor and rare disease both in China and worldwide. Based on the statistics provided by World Health Organization'sInternational Agency for Research on Cancer, there were approximately 19.29 million new cancer cases and 10 million cancer deaths globally in 2020. China had approximately 4.57 million new cancer cases in 2020, accounting for approximately 23.7% of the total cancer cases around the world. China'sNational Health Commission indicated that there are approximately 20 million patients with rare disease in China. Medical treatment markets for both cancer and rare diseases have been expanding along with the increasing number of patients. The Company has realized that, in addition to drug development and more advanced medical treatment options, patients' active engagements in the treatment is also critical to lead to better overall treatment outcomes such as higher chemotherapy completion rate, lower rehospitalization risk and longer survival time. Many multinational pharmaceutical companies have also realized such significance by conducting strategic investments in not only drug developments but also patient management projects. With our MDMOOC online platform which provides information, education, and training services for healthcare professionals and Sunshine Health Forums which provides healthcare knowledge for the public, the Company could provide technical supports for Zhongxin's patient management services to assist patients with tumor or rare disease. Zhongxin plans to build a comprehensive patient management system with integrated data insights into existing clinical workflows. Reported Earnings • May 03
Full year 2020 earnings released: EPS US$0.18 (vs US$0.19 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: US$18.0m (up 21% from FY 2019). Net income: US$4.46m (up 10% from FY 2019). Profit margin: 25% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improved over the past week After last week's 54% share price gain to US$2.66, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 23x in the Consumer Services industry in the US. Total returns to shareholders of 21% over the past year. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$1.91, the stock is trading at a trailing P/E ratio of 11.5x, down from the previous P/E ratio of 13.7x. This compares to an average P/E of 25x in the Consumer Services industry in the US. Total return to shareholders over the past year is a loss of 51%. Is New 90 Day High Low • Feb 13
New 90-day high: US$2.22 The company is up 10.0% from its price of US$2.02 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 21% over the same period. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improved over the past week After last week's 15% share price gain to US$2.14, the stock is trading at a trailing P/E ratio of 12.9x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 24x in the Consumer Services industry in the US. Is New 90 Day High Low • Jan 07
New 90-day low: US$1.68 The company is down 8.0% from its price of US$1.82 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is down 7.0% over the same period. Valuation Update With 7 Day Price Move • Dec 25
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$1.76, the stock is trading at a trailing P/E ratio of 10.6x, down from the previous P/E ratio of 12.7x. This compares to an average P/E of 27x in the Consumer Services industry in the US. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improved over the past week After last week's 20% share price gain to US$2.11, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 28x in the Consumer Services industry in the US. Valuation Update With 7 Day Price Move • Nov 19
Market pulls back on stock over the past week After last week's 18% share price decline to US$1.77, the stock is trading at a trailing P/E ratio of 10.7x, down from the previous P/E ratio of 13x. This compares to an average P/E of 28x in the Consumer Services industry in the US. Valuation Update With 7 Day Price Move • Nov 13
Market bids up stock over the past week After last week's 16% share price gain to US$2.15, the stock is trading at a trailing P/E ratio of 13x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 28x in the Consumer Services industry in the US. Is New 90 Day High Low • Oct 03
New 90-day low: US$1.70 The company is down 21% from its price of US$2.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 12% over the same period. Reported Earnings • Sep 22
First half earnings released Over the last 12 months the company has reported total profits of US$3.77m, down 10% from the prior year. Total revenue was US$16.4m over the last 12 months, up 12% from the prior year. 